FDA Recalls Duloxetine Over Cancer-Causing Chemical Concerns

The FDA has recalled over 7,100 bottles of duloxetine due to contamination with N-nitroso-duloxetine, a potential carcinogen.

The recall affects duloxetine, commonly known as Cymbalta, used to treat depression and anxiety.
The presence of N-nitroso-duloxetine, a nitrosamine impurity, was found above acceptable limits, prompting the recall.
The recall is classified as Class II, indicating the potential for temporary or medically reversible adverse health effects.
Towa Pharmaceutical Europe, the manufacturer, is collaborating with the FDA and other regulators to manage the recall.
Patients are advised to consult healthcare professionals before discontinuing use of the affected medication.